TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05563285

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Mindfulness-Based Intervention
Description: 1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Mindfulness-Based Intervention
Description: 1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group maintained their classes as usual, usual physical education sessions, and usual daily life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
Study: NCT04876235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasound
Description: All patients were implanted with stents（DPPS or LAMS）under the EUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound
Description: All patients were implanted with stents（DPPS or LAMS）under the EUS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lumen-apposing metal stent
Description: In the LAMS group, patients were stented with LAMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double-pigtail plastic stents
Description: In the DPPS group, patients were stented with DPPS
Study: NCT04812275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin closure
Description: Skin closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin closure
Description: Skin closure
Study: NCT05902156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DiaPaDeSS
Description: Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DiaPaDeSS
Description: Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
Study: NCT04788381

Intervention type: DRUG
Intervention: Bevacizumab
Description: Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
Study: NCT04913389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
Study: NCT06384573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecanemab
Description: Administered intravenously
Study: NCT05337085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study: NCT05829356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3 mRNA / LNP Vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3 mRNA / LNP Vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3 mRNA / LNP Vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3 mRNA / LNP Vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3 mRNA / LNP Vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent recombinant influenza Vaccine (RIV4)
Description: Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular
Study: NCT04705207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reflexology massage
Description: the patient receive only foot reflexology massage

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham massage
Description: the patient receive only foot traditional massage
Study: NCT05420285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
Study: NCT04839939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis
Description: Solid prescribed AFO with a wearing schedule of 6-12 hours per day
Study: NCT05607537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386 Tablet
Description: E7386 40 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (14C)E7386 Capsule
Description: (14C)E7386 40 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (14C)E7386
Description: (14C)E7386 administered intravenously.
Study: NCT04839939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Taping
Description: Combination between elastic and inelastic taping
Study: NCT06185465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan Wound Irrigation Solution
Description: After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
Study: NCT05971550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absence of antibiotic treatment
Description: Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
Study: NCT05510089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: D1\~D2: 75mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: D1\~D2: 300mg/m\^2, q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: D6: 6mg
Study: NCT04896528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: * Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment.
Study: NCT04992117

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study: NCT06472674

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06110013

Intervention type: DEVICE
Intervention: Electrical cardiometry
Description: All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management

Intervention type: DEVICE
Intervention: Electrical cardiometry
Description: All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management

Intervention type: DEVICE
Intervention: Electrical cardiometry
Description: All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management
Study: NCT04872361

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low PEEP
Description: Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP
Description: PEEP of 10 cm H2O will be applied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP/RM
Description: PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasonogrphy assessment
Description: The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasonogrphy assessment
Description: The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasonogrphy assessment
Description: The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss
Study: NCT06268652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organoid-guided personalized treatment
Description: After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2，IV, days 1, 8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m² , PO, bid, days1-14, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4mg/m², IV, days 1 and 8, q3w
Study: NCT05668832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UVB-exposed button mushrooms
Description: Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UVB-exposed button mushrooms
Description: Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
Study: NCT05869435

Intervention type: DEVICE
Group type: OTHER
Intervention: FastWire System Device - Peripheral
Description: The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
Study: NCT04447196

Intervention type: OTHER
Intervention: MDP
Description: Multi dimensional dyspnea profile scores at rest and during non invasive ventilation
Study: NCT04962685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion
Description: Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months.
Study: NCT05404750

Intervention type: BEHAVIORAL
Intervention: Harm Reduction
Description: Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
Study: NCT05357430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
Study: NCT05399420

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
Study: NCT04713891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 120 mg
Description: KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 240 mg
Description: KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 450 mg
Description: KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 600 mg
Description: KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 (dosage RP2D-2) + Atezolizumab
Description: KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 (dosage RP2D-1) + Atezolizumab
Description: KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 (dosage RP2D) + Atezolizumab
Description: KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study: NCT06392074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB04
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US License Enbrel
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU Source Enbrel
Description: Subcutaneous injection
Study: NCT06252948

Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.

Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.

Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.

Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.

Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.

Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.